Galapagos NV (NASDAQ:GLPG) Shares Bought by Finepoint Capital LP

Finepoint Capital LP increased its position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 21.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 674,762 shares of the biotechnology company's stock after buying an additional 117,000 shares during the quarter. Galapagos comprises 1.1% of Finepoint Capital LP's investment portfolio, making the stock its 10th biggest holding. Finepoint Capital LP owned about 1.02% of Galapagos worth $18,556,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GLPG. R Squared Ltd purchased a new position in shares of Galapagos during the fourth quarter worth about $26,000. GAMMA Investing LLC increased its holdings in shares of Galapagos by 77.4% in the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 974 shares during the period. QRG Capital Management Inc. lifted its holdings in shares of Galapagos by 21.7% during the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 1,866 shares during the period. American Century Companies Inc. grew its position in Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock valued at $711,000 after buying an additional 1,431 shares during the last quarter. Finally, Crossmark Global Holdings Inc. increased its stake in Galapagos by 31.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 49,163 shares of the biotechnology company's stock valued at $1,352,000 after buying an additional 11,777 shares during the period. Hedge funds and other institutional investors own 32.46% of the company's stock.

Galapagos Price Performance

Shares of GLPG stock traded up $0.20 during midday trading on Friday, reaching $23.98. 452,738 shares of the company traded hands, compared to its average volume of 192,420. The firm's 50 day simple moving average is $25.20 and its two-hundred day simple moving average is $26.50. Galapagos NV has a 1-year low of $22.36 and a 1-year high of $31.38.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Barclays reaffirmed an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. TD Cowen lowered Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Finally, Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and reduced their price target for the company from $31.00 to $22.00 in a report on Friday, February 14th. Four equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. According to MarketBeat, Galapagos has a consensus rating of "Hold" and a consensus target price of $25.33.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.